<DOC>
	<DOCNO>NCT01766245</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate bioequivalence ( assessment expect biological equivalence two pharmaceutical drug product identical active ingredient ) subcutaneous injection semaglutide produce two manufacturing process .</brief_summary>
	<brief_title>A Randomised , Single Centre , Double-blind , Two-period , Cross-over Trial Healthy Subjects Investigating Bioequivalence Between Subcutaneous Injections Semaglutide Produced Two Manufacturing Processes</brief_title>
	<detailed_description />
	<criteria>Healthy subject Body mass index ( BMI ) 18.530 kg/m^2 ( incl . ) History presence cancer , diabetes , pancreatitis clinically relevant cardiovascular disease major disorder Use prescription nonprescription medicinal product ( except routine vitamin , acetylsalicylic acid paracetamol ) within 3 week ( within 5 halflives medicinal product , whichever long ) prior first dose semaglutide Smoking , drug alcohol abuse Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method duration trial 3 month follow last dose semaglutide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>mm</keyword>
</DOC>